

**Table S1.** Schedules and allometry-scaled doses of antiretroviral drugs employed *in vivo*.

<b>Drug combination</b>	<b>Dose in humans (w)</b>	<b>Dose in mice (w/W)</b>	<b>Schedule (h)</b>
TDF+3TC+EFV	300 mg TDF	31.2 mg/kg TDF	24/24
	300 mg 3TC	31.2 mg/kg 3TC	24/24
	600 mg EFV	62.4 mg/kg EFV	24/24
TDF+3TC+ETV	300 mg TDF	31.2 mg/kg TDF	24/24
	300 mg 3TC	31.2 mg/kg 3TC	24/24
	200 mg ETV	20.8 mg/kg ETV	12/12
TDF+3TC+RPV	300 mg TDF	31.2 mg/kg TDF	24/24
	300 mg 3TC	31.2 mg/kg 3TC	24/24
	25 mg RPV	2.6 mg/kg RPV	24/24
AZT+3TC+LPV/r	90 mg AZT	9.9 mg/kg AZT	12/12
	45 mg 3TC	4.9 mg/kg 3TC	12/12
	120 mg LPV	13.1 mg/kg LPV	12/12
	20 mg RTV	2.2 mg/kg RTV	12/12



**Table S2 (continued). Evaluation of ARV compounds' activity against *P. berghei* mosquito stages *in vitro*.** Additional statistical data regarding the results presented in Fig.1B-D.

Oocyst Development	PIs									NNRTIs				NRTIs					INSTI
	DMSO	RTV	LPV	ATV	DRV	SQV	NFV	APV	IDV	ETV	RPV	EFV	NVP	ABC	TDF	AZT	FTC	3TC	RAL
N replicate wells	18	11	11	9	7	11	9	8	12	15	12	9	9	9	6	6	8	11	12
Median	97.6	51.3	68.8	60.5	67.4	42.5	77.6	78.0	40.3	76.6	38.7	54.5	82.3	175.3	115.4	78.8	125.0	127.4	121.5
Percentile	93.0 - 109.6	43.5 - 54.9	42.7 - 69.9	56.2 - 69.6	59.5 - 79.6	36.8 - 50.3	73.2 - 92.2	61.5 - 109.4	36.4 - 46.9	36.0 - 91.4	32.5 - 44.0	36.4 - 60.9	68.3 - 100.5	156.2 - 196.6	100.7 - 136.7	53.3 - 109	110.3 - 133.3	102.2 - 191.3	116.6 - 132.1
% Difference from Median		-46.3	-28.7	-37.1	-30.2	-55.1	-20.0	-19.6	-57.3	-20.9	-58.8	-43.1	-15.3	+77.7	+17.8	-18.8	+27.4	+29.8	+23.9
Mean	100	47.9	61.5	62.8	68.3	44.5	82.3	83.0	42.0	66.0	38.7	53.6	83.8	175.9	117.4	78.8	120.8	144.0	116.7
Std. Dev.	11.1	9.6	17.1	8.5	10.6	9.2	12.1	22.9	6.4	30.9	9.4	21.6	15.8	28.9	17.9	31.3	18.0	46.2	22.8
% Difference from Mean		-52.1	-38.5	-37.1	-31.7	-55.5	-17.7	-16.9	-57.9	-33.9	-61.2	-46.3	-16.2	+75.9	+17.4	-21.1	+20.8	+44.0	+16.7
Kruskal-Wallis test p-value		0.0006 (***)	ns	ns	ns	0.0001 (***)	ns	ns	0.0001 (****)	0.0408 (*)	0.0001 (****)	0.0108 (*)	ns	ns	ns	ns	ns	ns	ns

**Table S3. Evaluation of ARV compounds' activity against *P. berghei* mosquito stages *in vivo*.** Additional statistical data regarding the mosquito infection results presented in Fig. 3E-G.

	DMSO	TDF+3TC+EFV	TDF+3TC+ETV	TDF+3TC+RPV	AZT+3TC+LPV/r
<b>n (with zeros)</b>	54	69	79	61	68
<b>Range (with zeros)</b>	0-515	0-416	0-536	0-331	0-514
<b>Median (with zeros)</b>	90.5	48.0	33.0	57.0	5.0
<b>Percentile (25%-75%)</b>	9.7-310.3	14.0-115.5	0.0-170.0	8.0-160.5	0.0-36.5
<b>% decreased median</b>		47.0%	63.5%	37.0%	94.5%
<b>Mean (with zeros)</b>	155.5	75.0	108.2	95.4	49.5
<b>Std. Deviation</b>	162.6	82.4	145.3	103.5	99.4
<b>% decreased mean</b>		51.8%	30.4%	38.7%	68.2%
<b>Kruskal-Wallis test p-value</b>		ns	ns	ns	<0.0001 (***)
<b>Prevalence</b>	77.9%	84.3%	71.4%	76.4%	68.0%
<b>Std. Deviation</b>	2.0%	3.1%	1.4%	6.85%	10.3%
<b>Chi-square test p-value</b>		ns	ns	ns	ns
<b>n (without zeros)</b>	42	59	56	49	43
<b>Range (without zeros)</b>	6-515	1-416	1-536	3-331	1-514
<b>Median (without zeros)</b>	150.5	70.0	120.0	85.0	16.0
<b>Percentile (25%-75%)</b>	52.7-339.8	24.0-132.0	22.2-227.5	33.0-202.0	6.0-141.0
<b>% decreased median</b>		53.5%	20.3%	43.5%	89.4%
<b>mean (without zeros)</b>	199.9	87.7	152.6	118.7	78.3
<b>Std. Deviation</b>	158.4	82.6	151.8	102.8	116.0
<b>% decreased mean</b>		56.1%	23.7%	40.6%	60.8%
<b>Kruskal-Wallis test p-value</b>		<0.01 (**)	ns	ns	<0.0001 (***)